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INFLUENCE OF DURAFLO II 
HEPARIN-TREATED 
EXTRACORPOREAL 
CIRCUITS ON THE 
SYSTEMIC INFLAMMATORY 
RESPONSE IN PATIENTS 
HAVING CORONARY BYPASS 
Cardiopulmonary bypass generates a systemic inflammatory response, 
including the activation of leukocytes, contributing to postoperative mor- 
bidity. To evaluate whether the use of heparin-treated extracorporeal 
circuits could reduce the inflammatory reaction in patients undergoing 
cardiopulmonary bypass, we conducted a prospective clinical study on 14 
patients having coronary artery bypass in whom perfusion was done 
randomly with either Duraflo II heparin-treated circuits or with nontreated 
circuits. In both groups systemic heparinization was performed before 
cardiopulmonary bypass. The use of heparin-treated circuits resulted in a 
reduction of systemic inflammatory activation during cardiopulmonary 
bypass. This was reflected by lower plasma levels of soluble tumor necrosis 
factor receptors (p < 0.05) and of interleukin-6 and interleukin-8 (p < 
0.05), manifest after release of the aortic crossclamp. Furthermore, 6 and 
12 hours after aortic crossclamp release significantly lower levels of the 
soluble E-selectin (p < 0.05) were observed in the Duraflo II group. In 
patients in whom noncoated circuits were used, a significant decrease in 
circulating soluble intercellular adhesion molecule 1 (p < 0.05) was found 
early during bypass. All these observations suggest that the use of a 
heparin-treated extracorporeal circuit reduces the systemic inflammatory 
activation and may alter the leukocyte-endothelium interaction. (J THORAC 
CARDIOVASC SURG 1995;110:1633-41) 
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D uring cardiopulmonary b pass (CPB), leukocyte contact with synthetic surfaces initiates a host 
defense reaction with the characteristics of a sys- 
temic inflammatory response syndrome. Leukocyte 
activation during CPB includes release of proteo- 
lytic enzymes and changes in leukocyte adhesiveness 
and leukocyte sequestration i tissue beds, espe- 
cially in the lungs, with the potential danger of 
microvascular plugging and capillary leakage. Be- 
sides contact activation, ischemia-reperfusion njury, 
the reinfusion of shed blood, and hemodilution may 
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contribute to the increased leukocyte adherence to 
vascular endothelium. The adhesion of leukocytes to 
endothelium creates a microenvironment i  which 
damaging products of activated leukocytes are re- 
leased in close contact with vascular endothelium, 
which results in further endothelial activation or 
even endothelial injury. 1-4 
Although the large size of leukocytes and their 
relative lack of deformability make these cells easy 
to be trapped physically within the endothelial lin- 
ing, 5-7 the interaction between leukocytes and endo- 
thelium is largely mediated by biochemical proc- 
esses. 8-1° The adhesive interactions between 
leukocytes and endothelial cells are mediated in 
large part by specific leukocyte and endothelial 
adhesion molecules, it-is It has been shown that the 
adhesion molecules such as soluble intercellular 
adhesion molecule 1 (sICAM-1) and E-selectin are 
inducible on the endothelial surfaceJ 6-19 The proin- 
flammatory cytokines tumor necrosis factor (TNF), 
interleukin-6 (IL-6), and interleukin-8 (IL-8) are 
known to stimulate ndothelial cells to increase the 
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expression of these molecules and thus facilitate 
leukocyte adherence. 2°-22 Moreover, IL-8 is a major 
neutrophil chemotactic and activating factor pro- 
duced by various types of human cells. 
Modification of the material surface of the heart- 
lung machine has been recognized as a technique to 
change the interaction with blood. Originally, this 
method was designed to allow application of throm- 
boresistant characteristics to the materials. 23-26 
Later, it was found that heparin coating of the 
material surface reduced complement activation 
and might thus bear the potential to change leuko- 
cyte activation 27' 2s and subsequently the leukocyte- 
endothelium interaction. Therefore, the purpose of 
this study was to evaluate whether the use of hepa- 
rin-treated (Duraflo II surface, Bentley Laborato- 
ries Division, Baxter Healthcare Corp., Irvine, 
Calif.) extracorporeal circuits could reduce the leu- 
kocyte-mediated inflammatory response in patients 
undergoing CPB. 
Patients and methods 
Patients. Fourteen adult patients ubsequently under- 
going elective coronary artery bypass grafting were en- 
rolled in this study. The patients were randomly divided 
into two groups with (A, n = 7) or without (B, n = 7) the 
use of a heparin-treated xtracorporeal circuit. Exclusion 
criteria were the following: previous cardiac surgery, 
congestive cardiac failure, neurologic disorders (e.g., ce- 
rebrovascular ccident), severe pulmonary disorders (e.g., 
chronic obstructive pulmonary disease, emphysema), dia- 
betes, renal diseases (e.g., renal failure), liver diseases, 
and preoperative coagulopathies. Informed consent was 
obtained from each patient he day before the operation. 
The study was approved by the local ethical and research 
council. 
Anesthesia and monitoring. Standard anesthetics 
(lorazepam, fentanyl citrate, sufentanil citrate, alfentanil 
hydrochloride, midazolam hydrochloride, pancuronium 
bromide) and monitoring techniques (electrocardiogram, 
central venous-pulmonary arterial pressure monitoring, 
urinary output, rectal and skin temperature monitoring) 
were used in both groups. Cefuroxime was used for 
antibiotic treatment, and the first dose was administered 
before sternotomy. 
Before connection of the extracorporeal circuit for 
CPB, heparin (300 IU/kg, Heparin Leo, Leo Pharmaceu- 
tical Products BV, Weesp, The Netherlands) was admin- 
istered to achieve an activated coagulation time (ACT) 
greater than 480 seconds (Hemochron 400, International 
Technidyne Corp., Edison, N.J.). 
CPB. The main components in the extracorporeal cir-
cuit consisted of a hollow-fiber membrane oxygenator 
(Univox, Baxter Bentley), a venous reservoir (BMR-1900, 
Baxter Bentley), a cardiotomy reservoir (in group A: 
BCR-3500 Gold, Baxter Bentley; in group B: William 
Harvey H4700; C. R. Bard Inc., Tewksbury, Mass.), and 
an arterial ine filter (in group A: AF 1040 Gold, Baxter 
Bentley; in group B: Sartorius; Sartorius AG, G6ttingen, 
Germany). In group A, all components exposed to blood 
were pretreated with heparin-bonded coating (Duraflo 
II). The standard priming of the extracorporeal circuit was 
1300 ml Haemaccel 3.5% solution (Behringwerke AG, 
Marburg, Germany), 200 ml mannito120%, 100 ml human 
albumin 20%, 50 ml NaHCO 3 8.4%, 20 ml KC1 7.45% (B. 
Braun Medica BV, Uden, The Netherlands), and 6500 IU 
Heparin Leo. After institution of CPB at a flow rate of 2.4 
L/rain per square meter and after a blood temperature 
below 28°C (25 ° to 28 ° C) had been reached, the heart 
was topically cooled with 4 ° C saline solution 0.9% until it 
fibrillated. The aorta was then crossclamped, and a single 
dose of approximately 800 ml (600 to 1000 ml) of St. 
Thomas' Hospital No. 1 cardioplegic solution at 4 ° C was 
infused into the aortic root during a 4-minute period (3 to 
5 minutes) to provide myocardial preservation. Topic 
cooling was maintained uring the infusion of the car- 
dioplegic solution. 
Target flow rates of 2.4 L/min per square meter were 
maintained at normothermia and correspondingly lower 
rates of 2.0 L/min per square meter (1.8 to 2.2 L/rain per 
square meter) were maintained at moderate hypothermia 
(28 ° C), depending on the venous oxygen saturation and 
the arterial pressure. Pulsatile perfusion was used 
throughout the period of aortic crossclamping. During the 
conduct of CPB, attention was given to restrict and, if 
possible, to avoid the use of cardiotomy suction. Cardiot- 
omy suction and aortic root venting comprised in all cases 
less than 2% of the calculated flow (<90 ml/min, inter- 
mittent). A volume pressure control unit was used, with 
negative pressures less than 60 mm Hg. In all patients the 
left anterior descending coronary artery was revascular- 
ized with the left internal mammary artery. Papaverine 
was locally applied to the mammary artery after dissection 
to prevent spasm. After completion of all the distal 
anastomoses, the aortic crossclamp was removed and the 
proximal anastomosis was performed with a partial occlu- 
sion clamp after spontaneous or electrical defibrillation, 
while rewarming of the patient to 37 ° C continued. Addi- 
tional heparin was administered during CPB if the ACT 
was lower than 400 seconds. After CPB, heparin was 
reversed by a 3 mg/kg dose of protamine chloride (Hoff- 
man-La Roche BV, Mijndrecht, The Netherlands). Re- 
versal of the heparin effect was determined by heparin/ 
protamine titration (heparin assay cartridges, Medtronic 
HemoTec, Inc., Englewood, Colo.) on the Hepcon Sys- 
tem-Four (Medtronic HemoTec). All pump blood was 
returned to the patient through the aortic cannula or 
intravenously via infusion bags without hemoconcentra- 
tion. - 
Plasma samples. Blood samples were taken after 
induction of anesthesia, before aortic crossclamping, 
after release of the aortic crossclamp (i.e., start reper- 
fusion), and Vz, 11/2, 3, 6, 12, and 24 hours after release 
of the aortic crossclamp. Blood was collected in evacu- 
ated blood collection tubes containing ethylenediami- 
netetraacetic acid. Plasma was separated from blood 
cells by centrifugation at 1000 g for 5 minutes and 
stored at -70 ° C until analysis. 
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Measurement of inflammatory mediators. Inflam- 
matory mediators were measured with sandwich 
ELISAs,* which have been described elsewhere. 29-32 In 
short, immunoassay plates (Nunc-Immuno Plate Maxi- 
sorp, Roskilde, Denmark) were coated with monoclonal 
antibodies MRI-I, MR2-2, HM2, and ENA1 for measure- 
ment of soluble TNF receptors TNF-R55, sTNF-R75, 
slCAM-1, and sE-selectin, respectively. After being 
washed, the plates were incubated with plasma samples 
followed by incubation with specific biotin-labeled poly- 
clonal rabbit anti-sTNF-R immunoglobulin G (IgG), bi- 
otin-labeled monoclonal ntibody HM1, and monoclonal 
antibody ENA2, for sICAM-1 and sE-selectin detection, 
respectively. After the plates were washed, peroxidase- 
labeled streptavidin (Dako, Glostrup, Denmark) was 
added, and 3,3',5,5'-tetramethylbenzidine (Kirk gaard & 
Perry Lab., Gaithersburg, Md.) was used as a substrate. 
Photospectometry (450 nm) was performed with a 
micro-ELISA autoreader. Standard curves were con- 
structed using dilutions of human sTNF-R55, sTNF- 
R75, sICAM-1, and sE-selectin with known concentra- 
tions. The lower detection limits of the assays were 100 
pg/ml for TNF-Rs, 400 pg/ml for sICAM-1, and 1 ng/ml 
for sE-selectin. Similarly, ELISAs were used to determine 
plasma IL-6, IL-8, and TNF-c~ levels. For this purpose, 
plates were coated with monoclonal ntibodies 5E1, HM5, 
and 61E71, respectively. 
On incubation with plasma samples, the IL-6 and 
TNF-c~ assays were incubated with polyclonal rabbit 
antihuman IL-6 IgG or polyclonal rabbit antihuman 
TNF-a IgG followed by peroxidase-conjugated goat 
antirabbit IgG (Jackson ImmunoResearch, Westgrove, 
Pa.). For the detection of IL-8, biotin-labeled poly- 
clonal rabbit antihuman IL-8 followed by streptavidin- 
peroxydase conjugate was used. In these assays tetram- 
ethylbenzidine was used as a substrate. Human 
recombinant IL-6, human recombinant IL-8, and hu- 
man TNF-a were used for standard titration curves. 
The lower detection level was 10 pg/ml for IL-6, 100 
pg/ml for IL-8, and 20 pg/ml for TNF-c~. 
Statistics. The results were expressed as the mean _+ 
standard error. The Wilcoxon rank sum test was used 
for statistical analysis of differences between both ex- 
perimental groups. The Wilcoxon matched-pairs 
signed-rank test was used for analysis of differences 
between control values and different time points within 
one group. Ap value of less than 0.05 was considered to 
indicate a statistically significant difference between 
measured values. 
Results 
No significant difference xisted between the two 
groups as related to sex, age, body weight, height, 
CPB time, and aortic crossclamp time (Table I). 
Cytokines. Changes in IL-6 plasma concentra- 
tions with time in groups A and B are shown in Fig. 
1. In the patients who under,vent CPB without 
heparin-coated extracorporeal circuits (group B), a 
*ELISA = Enzyme-linked immunosorbent assay. 
Table I. Clinical characteristics of the patients groups 
Duraflo 1I Control 
(group A) (group B) 
No. 7 7 
Sex (M/F) 6/1 6/1 
Age (yr) 58 _+ 12 61 ± 11 
Height (cm) 176 _ 9 173 ± 14 
Weight (kg) 86 +-- 14 78 _+ 8 
Bypass time (min) 82 ± 24 82 -+ 20 
Aortic crossclamp time (rain) 51 + 18 53 + 20 
No significant difference existed between the two groups. The values are 
expressed in mean _+ standard deviation. 
rise in IL-6 concentration from the preoperative 
level of less than 10 pg/ml was detected from the 
time of the start of reperfusion. After the peak value 
of 1.60 _+ 1.31 ng/ml, which occurred 11/2 hours after 
the start of reperfusion, concentrations declined to 
preoperative values 24 hours after the release of the 
aortic crossclamp. In contrast, a modest increase in 
plasma IL-6 levels was observed in patients treated 
with the heparin-coated extracorporeal circuits 
(group A). IL-6 levels rose to 0.36 _+ 0.06 ng/ml 12 
hours after reperfusion and then gradually declined 
to preoperative l vels. 
As soon as CPB was started, circulating IL-8 
levels rose in patients of group B. A profound 
increase, however, was not found until the start of 
reperfusion. A peak level of 0.65 + 0.55 (ng/ml) was 
reached at 11/2 hours of reperfusion. Then plasma 
levels rapidly declined. Notably, in three of seven 
patients IL-8 levels were still elevated at 24 hours. In 
patients treated with the heparin-coated circuit 
(group A), a completely different pattern was ob- 
served. During the operation and early during 
reperfusion, no change in IL-8 levels occurred. At 6 
hours after reperfusion, a modest increase in IL-8 of 
0.21 _+ 0.18 ng/ml was found. At 24 hours after the 
start of reperfusion o significant differences were 
observed between the control and the Duraflo II 
group (Fig. 2). 
TNF, sTNF-R55, and sTNF-R75. In the present 
study no increase in TNF-c~ levels could be demon- 
strated (not shown). In only one patient, belonging 
to group B, was the detection level of our assay 
reached. The peak level was 74 pg/ml and this level 
was found V2 hour after reperfusion (data not 
shown). Interestingly, in this patient peak levels of 
soluble endothelial cell adhesion molecule, sTNF- 
R55, sTNF-R75, and IL-8, but not slCAM, were 
higher than the peak levels of these cytokines in any 
other patient. 
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Fig. 1. Circulating plasma levels of IL-6, mean (_+ standard error), in patients who underwent CPB with 
coated (A, hatched bars) and noncoated (B, cross-hatched bars) circuits. Statistically significant differences 
(p < 0.05) between the groups are indicated with an asterisk. X-clamp, Crossclamp. 
Preoperative l vels of sTNF-R were not signifi- 
cantly different between the two groups. CPB 
caused increases in plasma levels of both sTNF-R. 
However, kinetics of sTNF-R levels were different 
between the two groups. In group B (extracorporeal 
circuit without heparin coating), sTNF-R levels 
started to increase as early as during CPB. sTNF-R 
remained elevated from 1/2 to 6 hours after release 
of the aortic clamp and then slowly declined again. 
This pattern was similar for both sTNF-Rs. En- 
hancement of sTNF-R levels in plasma of patients 
with a heparin-coated circuit was significantly de- 
layed: no increase was found until 3 hours after 
release of the aortic clamp. From 6 to 24 hours 
onward, TNF-R levels were in the same range in 
both groups (Fig. 3, A and B). 
slCAM and sE-selectin. Wide variations in pre- 
operative plasma sICAM-1 levels (ranging from 80 
to 442 ng/ml) were found in patients who underwent 
CPB without heparin-coated xtracorporeal circuits 
(group B). After aortic crossclamping, sICAM-1 
levels fell immediately to 70 +_ 12 ng/ml (group B). 
In group A only a modest decrease was demon- 
strated (from 73 +_ 9 to 54 ± 7 ng/ml). Twenty-four 
hours after CPB, the plasma level of sICAM-1 
increased in both groups (group A: 107 _ 14 ng/ml; 
group B: 103 _+ 17 ng/ml). 
During the operation and subsequently during 
early reperfusion, circulating E-selectin levels 
showed a tendency to decrease without reaching a 
level of significance (Fig. 4). Later during reperfu- 
sion a gradual though profound increase was ob- 
served in both groups, with peak values between 12 
and 24 hours of reperfusion. In patients with a 
noncoated circuit these peak levels were signifi- 
cantly higher (p < 0.05) than the levels in the 
patients treated with the coated circuits (group A: 
40 +_ 13 ng/ml; group B: 54 +_ 17 ng/ml at 12 hours 
after reperfusion). 
Discussion 
CPB for cardiac operations is often associated 
with bleeding complications and generation of a 
systemic inflammatory response, which have been 
related to systemic heparinization and blood cell 
activation, activation of the coagulation system, fi- 
brinolytic disorders, and complement activa- 
tion.23, 25, 33-35 The exposure of blood to surfaces in 
the extracorporeal circuits might contribute to the 
generalized inflammatory esponse. Attempts to im- 
prove the biocompatibility of the circuits to reduce 
the systemic reactions have included endothelial cell 
seeding, heparin-like biomaterials, and heparin sur- 
face coating) 6' 37 
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Fig. 2. Circulating plasma levels of IL-8, mean (_+ standard error) in patients who underwent CPB with 
coated (.4, hatched bars) and noncoated (B, cross-hatched bars) circuits. Statistically significant differences 
(p < 0.05) between the groups are indicated with an asterisk. X-clamp, Crossclamp. 
Comparison of heparin-coated and uncoated ex- 
tracorporeal circuits during CPB has shown no 
significant reduction in platelet activation, fibrinol- 
ysis, postoperative blood loss, and donor blood 
transfusions in routine coronary bypass opera- 
tions.3S, 39 The only established and consistent clin- 
ical effect of heparin-treated circuits is that perfu- 
sion can be done with less systemic heparin in 
selected patients. This may result in improved he- 
mostasis and reduced blood loss and transfusion 
requirements. 4° Moreover, a significant reduction of 
C3 activation products using heparin-coated extra- 
corporeal circuits during CPB has been described. 41
In the present study we demonstrated that the use of 
Duraflo II heparin-treated extracorporeal circuits 
reduces the systemic inflammatory reaction during 
routine CPB procedures as measured by plasma 
levels of inflammatory mediators. 
In agreement with previous tudies, 42' 43 increased 
plasma IL-8 levels in patients undergoing CBP 
without heparin-coated xtracorporeal circuits were 
observed (see Fig. 2). IL-8, which is produced by 
monocytes, macrophages, fibroblasts, and vascular 
endothelial cells after stimulation with TNF-a, IL-1, 
or lipopolysaccharide, 44 is considered to be an im- 
portant and early mediator of neutrophil-mediated 
inflammatory reactions, because it strongly attracts 
neutrophils and enhances their activation. The use 
of a heparin-coated tubing system showed a remark- 
able reduction in circulating IL-8 levels. An increase 
of IL-8 did not occur until 3 to 6 hours after the nd 
of CPB. Because this intervention almost com- 
pletely prevented early IL-8 production, one may 
conclude that contact activation might be a major 
cause of proinflammatory activation in comparison 
to rewarming, reperfusion, or protamine supply, as 
has been suggested by Finn and associates. 43 
Trace amounts of TNF-a were found in a few 
patients in the present study, whereas in most 
patients and at most time intervals the TNF-a 
concentration was below the level of detection. In 
recent studies similar results were obtained. 43 Be- 
cause TNF-a has a very short half-life in the circu- 
lation, frequent serial measurements would be nec- 
essary to evaluate the precise role, if any, of TNF-c~ 
after CPB. Measurement of TNF-a-induced factors 
with slower kinetics may offer an opportunity to 
indirectly assess the role of TNF-a in the inflamma- 
tory response after CPB. 
TNF-a and inducers of TNF-a have been shown 
to cause shedding of TNF-R. 45-47 Therefore, en- 
hanced levels of sTNF-R may reflect a TNF-c~- 
induced inflammatory esponse. However, sTNF-Rs 
were also shown to be dependent on renal func- 
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Fig. 3. Circulating Plasma levels of soluble TNF-R55 (A) and TNF-R75 (B), (2 standard error) in patients 
who underwent CPB with coated (A, hatched bars) and noncoated (B, cross-hatched bars) circuits. 
Statistically significant differences (p < 0.05) between the groups are indicated with an asterisk. 
tion. 48 In the present s udy, increases in levels of 
both sTNF-Rs were found after CPB. Moreover, in 
patients with heparin-coated circuits the increase of 
STNF-R was significantly delayed. Because renal 
function of the two groups was not different (data 
not shown), these data suggest that heparin-coating 
prevents the onset of an early inflammatory re- 
sponse during CPB, 
IL-6 is produced by many cell types in response to 
IL-1 and TNF-a. It may be the main inducer of the 
acute-phase r sponse to injury, and its concentra- 
tion has been shown to to be elevated after major 
operations, reaching peak levels 24 hours after 
operation.49, 5oHere, IL-6 levels peaked as early as 
11/2 hours after the release of the crossclamp and 
returned toward normal values within 12 hours in 
patients treated with uncoated circuitS. The under- 
lying reason for these differences inkinetics remains 
unclear but may be dependent on the kind of 
trauma, medication , or the presence of neutralizing 
proteins like IL-6 receptors. Heparin coating of the 
extracorporeal circuit significantly attenuated sys- 
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Fig. 4. Circulating plasma levels of sE-selectin, mean (± standard error), in patients who underwent CPB 
with coated (A, hatched bars) and noncoated (B, cross-hatched bars) circuits. Statistically significant 
differences (p < 0.05) between the groups are indicated with an asterisk. X-clamp, Crossclamp. 
temic IL-6 levels. Whether this is associated with an 
attenuated acute-phase response remains to be es- 
tablished. 
The soluble adhesion molecule E-selectin in- 
creased above baseline starting 3 to 6 hours after 
crossclamping in both groups, whereas only a mod- 
est increase in sICAM-1 was observed 24 hours after 
CPB. E-selectin is found only on activated endothe- 
lium. E-selectin interacts with carbohydrate ligands 
and mediates the initial rolling of leukocytes on the 
endothelium. Endothelial cells have been shown to 
release E-selectin after in vitro stimulation. 29 There- 
fore, specific elevations i  levels of sE-selectin would 
indicate activation or damage to endothelium. The 
presence of higher levels of sE-selectin at 12 hours 
after CPB suggests that a more pronounced endo- 
thelial inflammatory eaction occurred with the non- 
heparin-coated circuits, sICAM-1 is constitutively 
expressed on vascular endothelial cells and a number 
of other cell types including fibroblasts, epithelial cells, 
and peripheral blood mononuclear cells and is partic- 
ularly involved in the firm attachment and transendo- 
thelial migration of leukocytesY Its expression is 
up-regulated after activation during an inflammatory 
response. 
In vitro studies have shown a direct correlation 
between the expression of sICAM-1 on endothelial 
cells and the subsequent shedding of sICAM-1 in 
the supernatant. 29 The ligand for sICAM-1 on the 
leukocyte surface is CD18. This CD18 expression 
increases when leukocytes are stimulated and can be 
used as a sensitive index of leukocyte activation. In 
a previous study, 52 increased CD18 expression on 
neutrophils and concomitant eutropenia after 60 
minutes of CPB was found. Heparin coating did not 
change the CD18 expression and neutropenia. The 
initial drop in circulating slCAM-1 in patients who 
underwent CPB with the uncoated circuits suggests 
an increase in activated leukocytes, because ligand 
binding by activated leukocytes may clear s!CAM-1 
from the plasma. On the other hand, CD18-positive 
leukocytes are immediately trapped by the vascular 
endothelial cells and are thus withdrawn from the 
circulation. Immunohistochemical studies are nec- 
essary to elucidate this point of discussion. 
In conclusion, this study demonstrates that hepa- 
rin coating of the extracorporeal circuit can signifi- 
cantly reduce the systemic inflammatory reaction 
caused by CPB. It is conceivable that the heparin- 
coated surface exerts its protective ffect by modi- 
fying mediators of the inflammatory cascade rather 
than from a direct interaction of heparin coating 
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and coagulation or fibrinolysis. A large clinical study 
is in progress to provide evidence that postoperative 
morbidity correlates with proinflammatory activity. 
We thank Mrs Gaby Schoen for her skillful assistance in
performing the enzyme-linked immunosorbent assays. 
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